Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Probucol for diabetic nephropathy (phase 2, 16-week, randomized, double-blind, placebo-controlled)
KCT0000927Phase 2Recruiting
- Sponsor
- Korea Otsuka Pharmaceutical
- Start
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic glomerulosclerosis comparing Probucol with Placebo (2 arms). Primary endpoint: Efficacy endpoints. Started Nov 2012; status: recruiting.
02
Drugs
probucol
03
Conditions
diabetic glomerulosclerosis
Beyond the preview
Go deeper on KCT0000927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0000927.